Provided by Tiger Fintech (Singapore) Pte. Ltd.

REIN THERAPEUTICS INC

1.95
-0.0500-2.50%
Post-market: 1.950.00000.00%17:04 EDT
Volume:22.53K
Turnover:43.71K
Market Cap:43.20M
PE:-0.68
High:1.99
Open:1.99
Low:1.91
Close:2.00
Loading ...

BRIEF-Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf

Reuters
·
27 May

Rein Therapeutics Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients With Ipf

THOMSON REUTERS
·
27 May

Rein Therapeutics Inc: Topline Interim Data From Renew Is Expected in First Half of 2026

THOMSON REUTERS
·
27 May

Rein Therapeutics : Sales Agreement Prospectus Covering Offering of up to $15.8 Mln of Common Stock

THOMSON REUTERS
·
16 May

Rein Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing

THOMSON REUTERS
·
16 May

Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Rein Therapeutics Reports Q1 2025 Financial Results: Cash Position Declines, R&D and G&A Expenses Decrease

Reuters
·
16 May

Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
16 May

Rein Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
10 May

Rein Therapeutics Announces Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis with Advanced AI Integration

Reuters
·
01 May

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of Lti-03 in Patients With Ipf

THOMSON REUTERS
·
01 May

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

PR Newswire
·
01 May

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

PR Newswire
·
28 Apr

BRIEF-Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases

Reuters
·
23 Apr

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder Lti-03 for the Treatment of Respiratory Diseases

THOMSON REUTERS
·
23 Apr

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

TIPRANKS
·
15 Apr

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

PR Newswire
·
15 Apr

Press Release: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
08 Apr